Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
FDC
Mr. Mohan Anand Chandavarkar · Mumbai, India
₹407.45
▼-1.65%FDC's current price decline may be an opportunity for investors to accumulate, given its strong revenue growth and decent profit margins in the specialty and generic drug manufacturing sector
Exchange
NSI
Currency
INR
Day range
₹405.35 – ₹415.00
52-week range
₹312.95 – ₹527.80
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis70% confidence
The stock appears to be reasonably valued, trading near the midpoint of its 52-week range, and may have upside potential given its growth prospects and industry trends
22.8% below the 1-year high · trend down
Hedge-fund memo
Today
The stock is down 1.65% today, possibly due to sector-wide trends or profit-taking
This week
FDC's stock has been range-bound in recent weeks, with a lack of clear direction
This month
The company's revenue growth and profit margins have been robust, with an 18.90% year-over-year increase in revenue
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
23 headlines · 20 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FDC | 66.34B | 23.58 | 11.81% | 15.73% | 18.90% |
| INDOCO | 19.97B | 637.32 | — | 1.39% | 6.80% |
| JBCHEPHARM | 387.93B | 54.22 | 18.69% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory challenges
Mitigation: Diversification of product portfolio and geographic expansion
Business intelligence
Competitive moat
FDC's established brand, extensive distribution network, and strong product pipeline provide a competitive moat in the Indian pharmaceutical market
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Release of quarterly financials
Thesis builder
Bull case
FDC's strong product pipeline and expanding distribution network will drive future growth
Base case
The company's established brand and customer base will support stable sales and profitability
Bear case
Intense competition and regulatory challenges may impact FDC's market share and pricing power
Time horizon
Medium-term (6-12 months)
Est. CAGR
10-15%
Entry (qual.)
On dips or during periods of sector-wide weakness
Exit (qual.)
If the stock reaches the upper end of its 52-week range or if there are significant changes in the company's fundamentals
Overall conviction 70%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how FDC fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain FDC for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Investors may consider accumulating the stock at current levels, with a long-term perspective
Miami New Times·10h ago·no relevance
TradingView·13h ago·neutral revenue report
WDTN.com·19h ago·no relevance
Chosunbiz·23h ago·no relevance
beavercreeknewscurrent.com·1d ago·no relevance
SunStar Publishing Inc.·1d ago·no relevance
MarketsMojo·2d ago·neutral rating
therichest.com·2d ago·no relevance
TradingView·2d ago·no relevance
Houston Public Media·2d ago·no relevance
INDToday·2d ago·no relevance
UNITED NEWS OF INDIA·2d ago·no relevance
Proshare·2d ago·neutral update
Proshare·2d ago·neutral update
The Texas Tribune·3d ago·no relevance
TMZ·3d ago·no relevance
foodrepublic.com·3d ago·no relevance
marketscreener.com·3d ago·buy rating
Nialler9·3d ago·no relevance
Business Today·3d ago·bullish recommendation
TradingView·5d ago·neutral revenue report
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 16.48% |
| -4.80% |
| APLLTD | 157.79B | 23.37 | 12.36% | 7.39% | 4.40% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹405.35
Resistance (day/52w high)
₹415.00
Volume
1,02,535
Trend
down
RSI (14)
33
MACD
bearish
MA cross
golden
50-day MA
₹406.53
200-day MA
₹391.45
vs 200-DMA
4.1%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.